secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001493152-22-034814
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran receives CDSCO approval for Phase 1b/2a trial of ProLectin-M in COVID-19 patients
--------------------------------------------------------------------------------

- IND authorization from India's CDSCO for a Phase 1b/2a randomized, blinded, placebo-controlled study of ProLectin-M in mild-to-moderate COVID-19.
- Trial will evaluate safety, efficacy, and pharmacokinetics of oral ProLectin-M; results to guide a 408-patient Phase III trial.
- Condition: each site must obtain Ethics Committee approval before starting enrollment.
- Press release issued December 8, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222034814/0001493152-22-034814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222034814/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-034814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer